Drug Profile
Research programme: mesenchymal stem cell-derived secretory factors - Sentien Biotechnologies
Alternative Names: Extracorporeal stem cell therapy - Sentien Biotechnologies; MSC-derived secretions; Sentinel; Stem cell therapeutics device - Sentien BiotechnologiesLatest Information Update: 13 Jan 2022
Price :
$50
*
At a glance
- Originator Sentien Biotechnologies
- Class Stem cell factors
- Mechanism of Action Immunosuppressants; Stem cell modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Acute kidney injury; Adult respiratory distress syndrome; Autoimmune disorders; Graft-versus-host disease; Liver disorders; Myocardial infarction; Pancreatitis; Renal failure
Most Recent Events
- 28 Feb 2021 No recent reports of development identified for preclinical development in Liver-disorders in USA (Parenteral)
- 28 Feb 2021 No recent reports of development identified for research development in Autoimmune-disorders in USA (Parenteral)
- 28 Dec 2020 No recent reports of development identified for preclinical development in Acute kidney injury in USA (Parenteral)